Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tamoxifen, screening and new oestrogen receptor modulators.
Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):365-80. doi: 10.1053/beog.2001.0182. Best Pract Res Clin Obstet Gynaecol. 2001. PMID: 11476559 Review.
Controversies regarding tamoxifen and uterine carcinoma.
Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R. Morales L, et al. Among authors: vergote i. Ann Oncol. 2005 Jan;16(1):70-4. doi: 10.1093/annonc/mdi021. Ann Oncol. 2005. PMID: 15598941 Free article. Clinical Trial.
Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006.
Neven P, Vergote I, Amant F, Berteloot P, de Jonge E, DE Rop C, DE Sutter P, Makar A, VAN Ginderachter J. Neven P, et al. Among authors: vergote i. Int J Gynecol Cancer. 2006;16 Suppl 2:479-91. doi: 10.1111/j.1525-1438.2006.00673.x. Int J Gynecol Cancer. 2006. PMID: 17010051 No abstract available.
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: vergote i. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
882 results